RVX Idea Mar 29 2023

Here’s a fun thought for Hump Day.

A while back I’d been researching the employee structures of Resverlogix vs. ZCC. I’ve lost sight of the details and don’t have time to retrace them now but there are a number of shared functions. At the highest level these companies have the same COB/CEO/President and the same VP of Accounting. There are other shared functions.

But, the most noticeable difference is that RVX does not have a business development function while ZCC has one of the remaining stars from the team that Dr Cherrington started to build before her abrupt departure…namely, Dr Sanjay Lakhotia (PhD, MBA).

As Tada pointed out recently on the ZCC site, ZCC has 12 trials in progress with various partners. ZCC has established working relationships with a number of BPs as well as the NCI and NIH. I have no idea how this success has been achieved. Is it because of the indications (cancers), is it the promise of zen3694 or might Dr Lakhotia’s skills be an instrumental factor in ZCC’s success?

We are all sadly aware that RVX has achieved nothing since the Bet-on-Mace trial failed and RVX has been unable to capitalize on the FDA Break Through Designation asset.

As pointed out by golfyeti (see below) his research shows that apabetalone shows promise in multiple indications as well. There are 35 listed in golfyeti’s research. So it is not the number of indications and huge potential that is the issue.

So why don’t we have apabetalone being in trials for at least 12 indications with multiple partners just like zen3694?

Here’s a Hump Day thought.

1. Don is paid $500,000 from RVX and $100,000 from ZCC.
2. Dr Lakhotia is paid $485,000 at ZCC.
3. RVX needs to get something achieved.
4. So, keep Dr Lakhotia at ZCC.
5. Also, hire Dr Lakhotia to be Sr. VP Business Development at RVX for $400,000.
6. Cut Don’s pay at RVX to $100,000 thus achieving this move at ZERO cost overall.

It’s a win x win for all!

Just a bit of hump day fun because it’s important to have a laugh or you’ll cry over this pathetic mess.

GLTA. Keep smiling.

Toinv

tada

Re: Toxicity

in response to 

Re: Toxicity

 by 

jonzobot

posted on Mar 24, 2023 02:30PM

Use the IP Check tool [?]

Sure would like to see a science update from Zenith with 12 trials going on now.

tada

golf

Potential Scope of Indications for Apabetalone (selective BRD/BD inhibition)

posted on Nov 14, 2022 04:02PM

Use the IP Check tool [?]

Someone requested this list.  I have collected links to supporting findings for each of these and most of these papers cite Apabetalone specifically as a promising treatment.

Cocaine Use disorder

Covid19 (and possibly most if not all coronavirus)

Long Covid19

Cardiovascular Disease

Chronic Kidney Disease

Alzheimer Disease

DIABETES MELLITUS  (DM)

FABRY DISEASE

COLORECTAL CANCER

Prostate Cancer

Lung Cancer

LIVER CANCER

OVARIAN CANCER (Chemotherapy resistant)

ANTI-AGING

HIV-1 (AIDS)

MUSCULAR DYSTROPHY (FHSD)

RESTENOSIS

Osteoporosis

Friedreich’s Ataxia

Thrombosis

Pulmonary arterial hypertension (PAH)

Degenerative diseases of the eye (retinal)

PERIODONTAL DISEASES

Non-alcoholic Fatty Liver Disease (NFLD)

Non-alcoholic steatohepatitis (NASH)

ASTHMA

Paroxysmal nocturnal hemoglobinuria (PNH)

ARTHRITIS (RA)

Calciphylaxis

Complement Mediated Disease

Neurofibromatosis - Malignant Peripheral Nerve Sheath Tumors (MPNST)

Sepsis, sepsis shock and MODS (Multiple Organ Dysfunction Syndrome in Sepsis)

Epilepsy